Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AbbVie's shares fall nearly 12 percent after decision to scrap plan for accelerated FDA approval of Rova-T

firstwordpharmaMarch 23, 2018

Tag: AbbVie , Rova-T

PharmaSources Customer Service